Karthik Sekar

1.2k total citations
17 papers, 720 citations indexed

About

Karthik Sekar is a scholar working on Molecular Biology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Karthik Sekar has authored 17 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Cancer Research and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Karthik Sekar's work include Cancer Mechanisms and Therapy (6 papers), RNA modifications and cancer (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Karthik Sekar is often cited by papers focused on Cancer Mechanisms and Therapy (6 papers), RNA modifications and cancer (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Karthik Sekar collaborates with scholars based in Singapore, China and United States. Karthik Sekar's co-authors include Kam M. Hui, London Lucien Ooi, Jianxiang Chen, Hongping Xia, Veerabrahma Pratap Seshachalam, Ming Shi, Brian K. P. Goh, Wanjin Hong, Shik Nie Kong and Xiaoqian Zhang and has published in prestigious journals such as The EMBO Journal, Gut and Scientific Reports.

In The Last Decade

Karthik Sekar

17 papers receiving 719 citations

Peers

Countries citing papers authored by Karthik Sekar

Since Specialization

Citations

This map shows the geographic impact of Karthik Sekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karthik Sekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karthik Sekar more than expected).

Fields of papers citing papers by Karthik Sekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karthik Sekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karthik Sekar. The network helps show where Karthik Sekar may publish in the future.

Co-authorship network of co-authors of Karthik Sekar

This figure shows the co-authorship network connecting the top 25 collaborators of Karthik Sekar. A scholar is included among the top collaborators of Karthik Sekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karthik Sekar. Karthik Sekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	MEDB-08. Inhibition of different mitotic targets demonstrated distinct DNA damage and cell death response in p53-mutant medulloblastoma 2022 ·Neuro-Oncology ·Shiying Huang, (unknown), Karthik Sekar, (unknown), Lin Qi, Ching C. Lau, (unknown), (unknown), Angela M. Major, M. Tarek Elghetany, Kam M. Hui, Xiao‐Nan Li, Wan‐Yee Teo	1
2	Maximizing the potential of aggressive mouse tumor models in preclinical drug testing 2021 ·Scientific Reports ·M. Tarek Elghetany, (unknown), (unknown), Karthik Sekar, Jack M. Su, Lin Qi, Yuchen Du, Jianhe Shen, (unknown), Ching C. Lau, Adekunle M. Adesina, Angela M. Major, Anat Erdreich‐Epstein, Kam M. Hui, Xiao‐Nan Li, Wan‐Yee Teo	3
3	Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers 2021 ·Cancer Research and Treatment ·Xiaodan Jiang, Yan Jiang, (unknown), Karthik Sekar, (unknown), Amudha Deivasigamani, Qingzhe Dong, (unknown), (unknown), Fengyun Hao, Brian K. P. Goh, London Lucien Ooi, Yu Wang, Kam M. Hui	18
4	EMBR-23. KIF11 DEPENDENCY ON P53 MUTATIONAL STATUS IN MEDULLOBLASTOMA 2021 ·Neuro-Oncology ·(unknown), Karthik Sekar, Lin Qi, Yuchen Du, Ching C. Lau, (unknown), (unknown), Angela M. Major, M. Tarek Elghetany, Kam M. Hui, Xiao‐Nan Li, Wan‐Yee Teo	1
5	Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations 2019 ·Scientific Reports ·Wan‐Yee Teo, Karthik Sekar, (unknown), Jianhe Shen, (unknown), Ching C. Lau, (unknown), Junseong Park, Seok‐Gu Kang, Xiaonan Li, Do‐Hyun Nam, Kam M. Hui	48
6	Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus 2019 ·Metabolomics ·(unknown), Jianxiang Chen, Karthik Sekar, Ming Shi, Tian Xie, Kam M. Hui	14
7	Genome‐wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth 2019 ·The FASEB Journal ·Yu Wang, Bin Gao, Peng Tan, (unknown), Karthik Sekar, Amudha Deivasigamani, Veerabrahma Pratap Seshachalam, (unknown), Ming Shi, Chan Xie, Brian K. P. Goh, London Lucien Ooi, Kam M. Hui	56
8	NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection 2019 ·International Journal of Cancer ·Yu Wang, Peng Tan, (unknown), Karthik Sekar, Ming Shi, Chan Xie, Xiaodan Jiang, Qingzhe Dong, Brian K. P. Goh, London Lucien Ooi, Zhiliang Gao, Kam M. Hui	29
9	CDK 1‐mediated BCL 9 phosphorylation inhibits clathrin to promote mitotic Wnt signalling 2018 ·The EMBO Journal ·Jianxiang Chen, (unknown), Hongping Xia, Shik Nie Kong, Amudha Deivasigamani, Karthik Sekar, Hengjun Gao, (unknown), Jayantha Gunaratne, London Lucien Ooi, Tian Xie, Wanjin Hong, Kam M. Hui	22
10	Insights into the etiology‐associated gene regulatory networks in hepatocellular carcinoma from The Cancer Genome Atlas 2018 ·Journal of Gastroenterology and Hepatology ·Veerabrahma Pratap Seshachalam, Karthik Sekar, Kam M. Hui	14
11	A genome-wide CRISPR cell growth screen identifies NCAPG as a new therapeutic target for hepatocellular carcinoma 2017 ·Annals of Oncology ·(unknown), Bo Gao, (unknown), (unknown), Karthik Sekar, Amudha Deivasigamani, Veerabrahma Pratap Seshachalam, (unknown), Mi Shi, Chan Xie, Brian K. P. Goh, London Lucien Ooi, (unknown)	2
12	Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib 2017 ·Cell Death Discovery ·Hongping Xia, (unknown), Jianxiang Chen, Shik Nie Kong, Karthik Sekar, Amudha Deivasigamani, Veerabrahma Pratap Seshachalam, Brian K. P. Goh, London Lucien Ooi, Kam M. Hui	43
13	MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence 2016 ·Cancer Letters ·Hongping Xia, Shik Nie Kong, Jianxiang Chen, Ming Shi, Karthik Sekar, Veerabrahma Pratap Seshachalam, (unknown), Brian K. P. Goh, London Lucien Ooi, Kam M. Hui	72
14	The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway 2016 ·Gut ·Jianxiang Chen, (unknown), Hongping Xia, Xiaoqian Zhang, Shik Nie Kong, Karthik Sekar, Veerabrahma Pratap Seshachalam, Amudha Deivasigamani, Brian K. P. Goh, London Lucien Ooi, Wanjin Hong, Kam M. Hui	174
15	ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma 2015 ·Journal of Hepatology ·Jianxiang Chen, Hongping Xia, Xiaoqian Zhang, Karthik Sekar, (unknown), London Lucien Ooi, Wanjin Hong, Kam M. Hui	93
16	EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma 2015 ·Journal of Hepatology ·Hongping Xia, Jianxiang Chen, Ming Shi, Hengjun Gao, Karthik Sekar, Veerabrahma Pratap Seshachalam, London Lucien Ooi, Kam M. Hui	68
17	A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma 2013 ·European Journal of Cancer ·Ming Shi, Min-Shan Chen, Karthik Sekar, Chee‐Kiat Tan, London Lucien Ooi, Kam M. Hui	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact